Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tongjitang Chinese Medicines Co.

www.tongjitang.com

Latest From Madrigal Pharmaceuticals Inc.

Miniature By Design: Tarveda's Small Conjugates Could Be Better Fit For HSP90

Biotech's internally derived Pentarins offer the targeting advantages of antibody-drug conjugates in cancer, but with better affinity, pharmacokinetics and deeper tumor penetration.

Platform Technologies Cancer

Madrigal Believes It Holds The Key To NASH: Clearing The Fat

Emerging Company Profile: With its first-in-class selective THR beta agonist, Madrigal thinks it may have a candidate, now in Phase II, that will offer reversal of liver damage in NASH patients with an excellent safety profile. It hopes to begin Phase III studies with MGL-3196 before the end of 2018.

StartUps and SMEs Business Strategies

Pipeline Watch: Phase III Read-Outs For Ozanimod, Olaparib And Sapacitabine

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals

Refocusing Tarveda On Tumor-Targeted Mini-Drug Conjugates

Emerging Company Profile: Tarveda Therapeutics has refocused during the past 18 months on its Pentarin technology. The company has raised $91.8m to date, including a recent $30m Series D round, which it will use to produce human data that could make it attractive to investors or pharma partners.

StartUps and SMEs Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • Tongjitang Chinese Medicines Co.
  • Senior Management
  • Xiaochun Wang, Chmn. & CEO
  • Contact Info
  • Tongjitang Chinese Medicines Co.
    Phone: (86) 755) 2689-1550
    Nanhai Ave. S., Nanshan District
    5th Fl. Block B
    Shenzhen, 518067
    China
Advertisement
Advertisement
UsernamePublicRestriction

Register